Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.

Clinical and experimental nephrology - 1 Feb 2020

Narita Ichiei, Ohashi Toya, Sakai Norio, Hamazaki Takashi, Skuban Nina, Castelli Jeffrey P, Lagast Hjalmar, Barth Jay A

Abstract excerpt

BACKGROUND: Fabry disease is a progressive X-linked lysosomal disorder. In this subgroup analysis of the global phase III ATTRACT study, the efficacy and safety of oral migalastat, a pharmacologic chaperone, were investigated in Japanese patients with Fabry disease. METHODS: Patients were randomly assigned to receive migalastat (150 mg every other day) or to continue biweekly enzyme replacement therapy infusions...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 1-Deoxynojirimycin
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to alpha-Galactosidase

Share to Fabry Disease

Share to Genetic Predisposition to Disease

Share to Time Factors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 31889231
DOI: 10.1007/s10157-019-01810-w
PMCID: PMC7007427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.PMID 31889231Read ↗

Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.Semantic proximity Read ↗

Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).Semantic proximity Read ↗

Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.Semantic proximity Read ↗

A review and recommendations for oral chaperone therapy in adult patients with Fabry disease.Semantic proximity Read ↗

FABRY DISEASE: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat. What Do We Know Today?Semantic proximity Read ↗

Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension studySemantic proximity Read ↗

Precision medicine in Fabry disease.Semantic proximity Read ↗

Fabry Disease Therapy: State-of-the-Art and Current ChallengesSemantic proximity Read ↗

Current and Investigational Therapeutics for Fabry DiseaseSemantic proximity Read ↗

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesSemantic proximity Read ↗

[Expert consensus for diagnosis and treatment of Fabry disease in China (2021)].Semantic proximity Read ↗

Fabry disease: Mechanism and therapeutics strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.